Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)
Historic Debt Ratio for Inhibikase Therapeutics (IKT) over the last 6 years, with Q2 2025 value amounting to 0.0.
- Inhibikase Therapeutics' Debt Ratio fell 9752.38% to 0.0 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.0, marking a year-over-year decrease of 9752.38%. This contributed to the annual value of 0.0 for FY2024, which is 8916.69% down from last year.
- According to the latest figures from Q2 2025, Inhibikase Therapeutics' Debt Ratio is 0.0, which was down 9752.38% from 0.0 recorded in Q1 2025.
- Inhibikase Therapeutics' Debt Ratio's 5-year high stood at 0.03 during Q3 2024, with a 5-year trough of 0.0 in Q2 2025.
- Moreover, its 5-year median value for Debt Ratio was 0.01 (2022), whereas its average is 0.01.
- As far as peak fluctuations go, Inhibikase Therapeutics' Debt Ratio skyrocketed by 29805.51% in 2024, and later tumbled by 9752.38% in 2025.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Debt Ratio stood at 0.01 in 2021, then rose by 15.64% to 0.01 in 2022, then surged by 76.92% to 0.01 in 2023, then crashed by 89.17% to 0.0 in 2024, then plummeted by 61.9% to 0.0 in 2025.
- Its last three reported values are 0.0 in Q2 2025, 0.0 for Q1 2025, and 0.0 during Q4 2024.